http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H11504031-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 1996-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1999-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H11504031-A |
| titleOfInvention | Quinazoline derivatives |
| abstract | (57) The present invention provides a quinazoline derivative of the formula I wherein n is 1, 2 or 3 and R 2 is independently halogeno; R 1 is amino- (2- 4C) alkylamino, (1-4C) alkylamino- (2-4C) alkylamino, di-[(1-4C) alkyl] amino- (2-4C) alkylamino, pyrrolidin-1-yl- (2- 4C) alkylamino, piperidino- (2-4C) alkylamino, morpholino- (2-4C) alkylamino, piperazin-1-yl- (2-4C) alkylamino or 4- (1-4C) alkylpiperazine-1 -Yl- (2-4C) alkylamino] or a pharmaceutically acceptable salt thereof, a process for preparing the same, a medicament containing the compound and a receptor tyrosine kinase inhibitory property of the compound as a cancer-like compound. Use in the treatment of various proliferative disorders. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8404698-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006515871-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011526913-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003513035-A |
| priorityDate | 1995-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 276.